Vandetanib almost doubles progression free survival in patients with thyroid cancer
Results of a phase 2 randomised trial for patients with advanced differentiated thyroid cancer (DTC) show that those treated with the oral targeted agent vandetanib survived without the disease getting worse for almost twice ...
Aug 13, 2012
0
0